Clinical Trial Update: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of NBTXR3 activated by radiation therapy for borderline resectable or locally advanced pancreatic cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• NBTXR3 (hafnium oxide nanoparticles)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: SUSPENDED